https://www.selleckchem.com/products/2-d08.html
The efficacy of olanzapine (mean dose 0.09 mg/kg/dose) was evaluated in 31 children 2-18 years of age, for chemotherapy induced breakthrough vomiting. Among 42 chemotherapy blocks with emesis, complete and partial responses were observed in 34 (80.9%) and 6 (14.3%) blocks, respectively, while 1/31(2.4%) patient had refractory vomiting. Mild sedation and transient transaminitis were the observed side effects.We assessed compliance to routine vitamin D supplementation in 330 infants (age 6 wk to 9 mo), who were prescribed supplemen-tation a